Bioreactors Market - By Product (Single-use, Reusable), By Cell (Mammalian Cells, Bacterial Cells, Yeast Cells), By Molecule (Monoclonal Antibodies, Vaccines, Recombinant Proteins, Stem Cells, Gene Therapy), By Usage, By End-use & Forecast, 2023-2032

Bioreactors Market - By Product (Single-use, Reusable), By Cell (Mammalian Cells, Bacterial Cells, Yeast Cells), By Molecule (Monoclonal Antibodies, Vaccines, Recombinant Proteins, Stem Cells, Gene Therapy), By Usage, By End-use & Forecast, 2023-2032

Bioreactors Market Size

Bioreactors Market size surpassed USD 8.5 billion in 2022 and is projected to expand at over 12% CAGR from 2023-2032.
 

A surge in the number of initiatives focusing on orphan drug development will have a positive impact on the bioreactors industry outlook. Over the last decade, scientific advances in the field of genetics and next-generation therapeutics such as the application of gene therapy and biomarkers have accelerated the demand for orphan therapies. The rapid proliferation of orphan therapies can be attributed to the growing need for the treatment of rare diseases and FDA approvals which validate and boost the sales of orphan drugs.
 

Growing concerns associated with extractables and leachables may impede the adoption of bioreactors. The use of disposable plastic bioreactors in the manufacturing of biopharmaceutical products poses a risk of contamination. The toxicology of plasticizers, slip agents, surface enhances, initiators, and monomers and the possible leaching of surface enhancers into the drugs could lead to adverse effects on patient health. Despite the wide range of benefits provided by single-use bioreactors, they may react unfavorably or fully neutralize biopharmaceuticals. This scenario negatively affects the adoption of bioreactors across biotech companies due to strict regulatory compliances monitoring biotech cell toxicity and human toxicology.
 

Bioreactors Market Analysis

Bioreactors market from reusable bioreactors segment was over USD 6.5 billion in 2022. Healthcare companies and commercial drug manufacturers are heavily inclined towards reusable bioreactors as they offer high volume capacity and enhanced scalability. Even though manufacturing with reusable bioreactors such as stainless-steel bioprocessing systems is energy-intensive, in the long term, it is more cost-effective than single-use bioreactors. Since single-use systems require the replacement of disposable plastic components for each batch, the cumulative energy expenditure is 4 times greater than that of bioprocessing processes using multi-use systems.
 

Bioreactors market from yeast cells segment is expected to register over 4% CAGR through 2032. Yeasts are the most used microorganisms in the production of a broad spectrum of products and are subject to R&D initiatives exploiting potential applications. One of the prominent uses of yeast cells is in the manufacturing of protein-based and fermented products. Water management, pharmaceutical, and food and beverage manufacturing facilities are increasingly using flocculation bioreactors owing to their high productivity and cell density. These reactors are mainly used in manufacturing processes that require effective management of yeast flocculation.
 

Bioreactors market from gene therapy segment is estimated to exceed USD 1 billion by 2032. Rising incidences of genetic disorders are compelling further advancements in gene therapy. In recent years, private & public organizations have expedited R&D along with investments in biotechnology for drug discovery and development of novel therapeutics. Increasing applications of genetic engineering across green biotechnology will bolstering the genetic manipulation of plant cultures using sophisticated bioreactors.
 

Contract manufacturing organizations (CMOs) are estimated to hold more than a 12.5% share of the bioreactors market by 2032. CMOs are an emerging trend in the healthcare sector for outsourcing product development. These firms enable manufacturers to establish a solid presence across developing economies. CMOs also help organizations that lack a robust infrastructure and technical skills. Due to the growing need for outsourcing, CMOs are accelerating the adoption of bioreactors to achieve cost-efficiency, which will complement the industry progress.
 

Europe bioreactors market surpassed USD 3 billion in 2022. European countries have experienced dynamic growth in the adoption of next-generation bioreactors, particularly disposable bioreactors. The presence of many biotechnology companies in the region should offer lucrative scope for bioprocessing equipment manufacturers. Increasing efforts to develop and manufacture novel therapeutics, monoclonal antibodies, vaccines, and stem cells in bulk will further consolidate a promising demand for bioreactors across the region.
 

Furthermore, several start-ups across Europe are ramping up efforts to build innovative bioreactors. For instance, Switzerland’s Planetary & DAB.bio based in the Netherlands are designing bioreactors for fermentation. Meanwhile, UK-based start-ups such as Unicron Biotechnologies, Cellular Agriculture, and Animal Alternative Technologies are building bioreactors to develop new products from cell cultures. 
 

Bioreactors Market Share

Some of the leading companies in the global bioreactors market include

• Danaher Corporation
• Merck Group
• Thermo Fisher Scientific
• Pierre Guerin SAS (Engie)
• Cellexus Ltd
• CESCO Bioengineering Co. Ltd
• Bbi Biotech
• Getinge (Applikon Biotechnology)
• Shanghai Bailun Biotechnology co., Ltd.
• PBS Biotech
• Solaris Biotech Solutions
• CerCell Aps
• Sartorius Group
• Eppendorf AG
• GEA Group Aktiengesellschaft

These companies are mainly focusing on partnerships and collaborations to boost innovation.
 

Impact of COVID-19 Pandemic

The COVID-19 pandemic had a significantly positive impact on bioreactors industry. With an exponential rise in hospitalization rate, mortality rate, and prevalence of chronic and infectious diseases driven by the virus, healthcare & medical needs soared dramatically in the wake of the pandemic. As a result, the adoption of single-use bioreactors increased significantly due to their ability to ensure improved flexibility in validation, process security, complexity, and cost of goods.
 

The bioreactors market report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments

By Product Type

• Single-use
• Reusable

By Cell

• Mammalian cells
• Bacterial cells
• Yeast cells
• Others

By Molecule

• Monoclonal Antibodies
• Vaccines
• Recombinant Proteins
• Stem Cells
• Gene Therapy
• Others

By Usage

• Developmental, Pre-clinical & Clinical
• Commercial Production

By End-use

• R&D Organizations
• Biopharma Manufacturers
• Contract Manufacturing Organizations (CMOs)

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • The Netherlands
  • Denmark
  • Others
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Singapore
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
  • South Africa
  • UAE
  • Others